Development of Biosimilars—Pharmacokinetic and Pharmacodynamic Considerations

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.20, Iss.1, 2010-01, pp. : 46-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

By Mahmood Iftekhar Green Martin D.

Clinical Pharmacokinetics, Vol. 44, Iss. 4, 2005-01 ,pp. : 331-347

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments

By Müller-Lissner Stefan

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 4, 2013-04 ,pp. : 391-401

Informa Healthcare

Access to resources Recommend Favorite

Penetration of Antibacterials into Bone: Pharmacokinetic, Pharmacodynamic and Bioanalytical Considerations

By Landersdorfer Cornelia B.

Clinical Pharmacokinetics, Vol. 48, Iss. 2, 2009-01 ,pp. : 89-124

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

By Yang Bing-Bing Lum Peggy Chen Alin Arends Rosalin Roskos Lorin Smith Brian Ruixo Juan José Pérez

Clinical Pharmacokinetics, Vol. 49, Iss. 11, 2010-11 ,pp. : 729-740

Adis International

Access to resources Recommend Favorite

Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications

By Denson Lee A

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 12, 2008-12 ,pp. : 1569-1580

Informa Healthcare

Access to resources Recommend Favorite